Red blood cell

Insights on the Hemoglobinopathies Global Market to 2031 - Increasing Prevalence of Hemoglobinopathies in Under-Developed and Developing Countries is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 21, 2022
Health, Pharmaceutical, Prevalence, Hemoglobinopathy, Gene expression, SCD, Degenerative disease, Sickle cell disease, Thalassemia, Beta thalassemia, Market share, B cell, Growth, Porter's five forces analysis, Diagnosis, Distribution, Red blood cell, Benchmarking, Retail, Copper, Pharmaceutical industry

The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth.

Key Points: 
  • The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth.
  • The key driver for the growth of the global hemoglobinopathies market is increasing prevalence of hemoglobinopathies in under-developed and developing countries.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemoglobinopathies market analysis from 2021 to 2031 to identify the prevailing hemoglobinopathies market opportunities.
  • The report includes the analysis of the regional as well as global hemoglobinopathies market trends, key players, market segments, application areas, and market growth strategies.

ESO Releases 2022 ESO Trauma Index to Explore Key Trends and Measures Affecting Trauma Centers Across the Country

Retrieved on: 
星期四, 十一月 17, 2022
Data Management, Health, Technology, Hospitals, Health Technology, Software, General Health, Hospital, ICU, Trauma, Hip, Intubation, Delirium, ESO, CPR, Injury Severity Score, Burn, Emergency medical services, Death, PRBC, Research, Safety, Data, Injury, Blood transfusion, EHR, HDE, Mortality, Cardiac arrest, Gq alpha subunit, ISS, EMS, Survival rate, Patient, Red blood cell, Blood product, Dentistry, Index

ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO Trauma Index , a report focused on key trends across hospital trauma programs nationwide.

Key Points: 
  • ESO , the leading data and software company serving emergency medical services (EMS), fire departments, hospitals, state and federal agencies, today announced the findings of its 2022 ESO Trauma Index , a report focused on key trends across hospital trauma programs nationwide.
  • The dataset for the ESO Trauma Index is from the ESO Data Collaborative .
  • The 2022 ESO Trauma Index looks at 884,456 deidentified patient records with hospital admission dates between January 1 December 31, 2021.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

New Age for Point-of-Care Diagnostics: PixCell Medical's HemoScreen Surpasses Leading Lab Hematology Analyzer Sysmex XN in Flagging of Abnormal WBC

Retrieved on: 
星期三, 十一月 16, 2022
Quality of life, Sysmex Corporation, WBC, Complete blood count, CBC, University, FDA, University of Turku, Red blood cell, Viscoelasticity, Solution, Medical device, Hematology

This ground-breaking study showed HemoScreen to be more accurate in regard to leukocyte abnormalities (flagging all abnormalities).

Key Points: 
  • This ground-breaking study showed HemoScreen to be more accurate in regard to leukocyte abnormalities (flagging all abnormalities).
  • It demonstrated better specificity (88% versus Sysmex XN's 72%) as it was less prone to false flagging versus the Sysmex XN, this is owing to HemoScreen's novel machine learning-driven viscoelastic focusing technology.
  • "HemoScreen hematology analyzer is essentially comparable to Sysmex XN for CBC and WBC differential analysis.
  • HemoScreen was less prone to false WBC flagging compared to Sysmex XN, thereafter requiring less microscopy review.

HEMANEXT ANNOUNCES CLOSE OF SERIES B EQUITY FUNDING ROUND

Retrieved on: 
星期一, 十一月 7, 2022
O2, Company, LR, Research, Exercise, CO2, Red blood cell, Merck, Board, Biotechnology, RBC, White blood cell, FDA, Safety, Ness, University of Cape Town, Johns Hopkins University, National, University, Division, CEO, Collection, UCB, Drug development, Board of directors, Transfusion medicine, Technology, Patient, Schering-Plough, University of Cambridge, Management, Pharmaceutical industry, Medical device, Nordic, Director, Medicine

LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced the successful first close of its Series B fundraising round. Taken together with the exercise of outstanding warrants, this close brings an additional $18 million of equity capital from noted global private investors with deep finance and healthcare expertise. To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).

Key Points: 
  • LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc ., a leading innovator in blood processing, storage, and transfusion technology, today announcedthe successful firstclose of its Series B fundraising round.
  • Taken together with the exercise of outstanding warrants, this close bringsan additional $18 millionof equity capitalfromnoted globalprivate investorswithdeepfinance and healthcare expertise.
  • To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).
  • The Companywill be keepingthe current Series B available to investors for thenext few weeks.Hemanextexpects to begin a Series C roundwithinstitutional investorsin 2023.

$2.83 Billion Worldwide Cord Blood Banking Services Industry to 2027 - Featuring Alphacord, Americord Registry, ATCC and California Cryobank Among Others

Retrieved on: 
星期一, 十月 24, 2022
Leukemia, Placenta, Cord blood, Therapy, Prevalence, B cell, Lymphoma, Red blood cell, Smoking, LifeBank, CAGR, Patient, Hospital, Research, Collection, Cancer, Lists of diseases, Bone marrow, R, Industry, Stem cell, Awareness, PerkinElmer, White blood cell, Umbilical cord, COVID-19, ATCC, Hematology, Pharmaceutical industry, Cryptocurrency, Potash, California Cryobank, Growth

The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.

Key Points: 
  • The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021.
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Moreover, there is an increase in the utilization of cord blood banking services for the treatment of immunodeficiency disorders across the globe.
  • What is the structure of the global cord blood banking services market and who are the key players?

Curate Biosciences Adds Mayo Pujols to its Board of Directors

Retrieved on: 
星期三, 十月 19, 2022
Lisocabtagene maraleucel, CA, Red blood cell, Technology, Celgene, Hand, Mayo, DCS, Novartis, Board, CEO, Board of directors, Bristol Myers Squibb, CTO, Pharmaceutical industry, Fine chemical, Curate

CARLSBAD, Calif., Oct. 19, 2022 /PRNewswire/ -- Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Mayo Pujols, Chief Technical Officer of late-stage gene therapy biotech Rocket Pharmaceuticals, has been appointed to its Board of Directors. Mr. Pujols has worked in biopharmaceutical manufacturing for nearly thirty years including managing cell and gene therapy manufacturing operations for Novartis, Celgene, and Andelyn Biosciences, before joining Rocket as Chief Technical Officer (CTO) and Executive Vice President in July of this year. His guidance will help Curate Biosciences through the initial commercialization of its Curate® Cell Processing System in early 2023, as it capitalizes on the platform's promise to broaden access to curative cell therapies.

Key Points: 
  • CARLSBAD, Calif., Oct. 19, 2022 /PRNewswire/ --Curate Biosciences, a key enabling technology company for cell therapy manufacturing, today announced that Mayo Pujols, Chief Technical Officer of late-stage gene therapy biotech Rocket Pharmaceuticals, has been appointed to its Board of Directors.
  • His guidance will help Curate Biosciences through the initial commercialization of its Curate Cell Processing System in early 2023, as it capitalizes on the platform's promise to broaden access to curative cell therapies.
  • "Mayo's experienced hand in CAR-T cell therapy manufacturing is a strong contribution to our company at this pivotal time," said Mike Grisham, CEO of Curate Biosciences.
  • "This is a great time to join Curate, as hundreds of companies are developing cell therapies and launching clinical trials," said Pujols.

Stem Cell Manufacturing Global Market Report 2022: Increasing Venture Capital Investments Fueling Sector Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 17, 2022
Biotechnology, Health, Stem Cells, Printing, Leukemia, Placenta, Government, B cell, Lymphoma, Animal, Red blood cell, Stem cell, CAGR, Neoplasm, Research, Tissue, MSC, Cell, Investment, Bone marrow, Plant, VC, Drug discovery, Blood, Awareness, Disease management, Umbilical cord, Tissue engineering, HSC, Public health, Pharmaceutical industry, Growth

The "Stem Cell Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stem Cell Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global stem cell manufacturing market size reached US$ 11.2 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 18.59 Billion by 2027, exhibiting a CAGR of 8.81% during 2021-2027.
  • Stem Cell Manufacturing Market Trends:
    The global market is primarily driven by the increasing venture capital (VC) investments in stem cell research due to the rising awareness about the therapeutic potency of stem cells.

Global Cord Blood Banking Services Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
星期四, 十月 13, 2022
Infectious Diseases, Health, Oncology, Stem Cells, Leukemia, Placenta, Cord blood, Prevalence, Growth, B cell, Lymphoma, Red blood cell, Smoking, Patient, Hospital, Research, Collection, Bone marrow, Cancer, Lists of diseases, R, Industry, Awareness, Stem cell, White blood cell, Umbilical cord, COVID-19, Hematology, Pharmaceutical industry, Cryptocurrency, Potash

Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.

Key Points: 
  • Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use.
  • Key Questions Answered in This Report:
    How has the global cord blood banking services market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global cord blood banking services market?
  • What is the structure of the global cord blood banking services market and who are the key players?

Biolog-id Announces Deployment of its Value-Chain-Optimization Solution at We Are Blood, a Major Blood Center Serving Central Texas

Retrieved on: 
星期四, 十月 6, 2022
We Sweat Blood, Red blood cell, Family, Organization, Patient, Diploma, RBC, Hospital, Technology, PLT, CEO, Central, GLOBE, Incubator, Solution, Documentation, Pharmaceutical industry, Medical device, Central Texas, Blood

We Are Blood collects blood donations and serves over 40 hospitals and medical facilities in a 10-county area with a mission to provide and protect the community blood supply.

Key Points: 
  • We Are Blood collects blood donations and serves over 40 hospitals and medical facilities in a 10-county area with a mission to provide and protect the community blood supply.
  • We Are Blood seeks and utilizes innovative technology to provide our communitys blood supply and serve Central Texas patients, said Marian Garrard, President & CEO of We Are Blood.
  • We Are Blood is the nonprofit blood center serving Central Texas and the exclusive provider of the communitys blood supply.
  • Today, We Are Blood collects blood donations and serves over 40 hospitals and medical facilities in the 10-county area.

Biolog-id Launches an Innovative High-Density (HD) RFID Kit Targeting the High-Volume Needs of Blood Centers and Large Hospital Blood Banks

Retrieved on: 
星期二, 十月 4, 2022
Solution, Architecture, Engineering, Blood, CEO, RFID, Organization, HD, RBC, Adoption, GLOBE, Red blood cell

ATLANTA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Biolog-id announced the launch of an innovative RFID kit designed specifically for organizations with high volumes of Red Blood Cells (RBC).

Key Points: 
  • ATLANTA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Biolog-id announced the launch of an innovative RFID kit designed specifically for organizations with high volumes of Red Blood Cells (RBC).
  • An innovative RFID base with a flexible mounting system allows the Biolog-id HD kit to accommodate multiple refrigerators and cold-room setups.
  • The unique RFID-friendly bins allow users to move large quantities of blood from one location to another with full RFID traceability, facilitating a seamless integration into existing processes.
  • The HD project was a strategic effort that we can now utilize for additional blood products, said Troy Hilsenroth, CEO at Biolog-id.